Docetaxel effectively mobilizes peripheral blood CD34+ cells

Bone Marrow Transplantation

Volumn 26, Issue 5, 2000, Pages 483-487

  Prince, H M ^a   Toner, G C ^a   Seymour, J F ^a   Blakey, D ^a   Gates, P ^a   Eerhard, S ^a   Chapple, P ^a   Wall, D ^a   Quinn, M ^a   Juneja, S ^a   Wolf, M ^a   Januszewicz, E H ^a   Richardson, G ^b   Scarlett, J ^b   Briggs, P ^b   Brettell, M ^a   Rischin, D ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Docetaxel; Mobilization; Stem cells

Indexed keywords

BEUPOGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; GROWTH STIMULATION; HEMATOPOIESIS; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUTROPENIA; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN METASTASIS; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0033832457     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702540     Document Type: Article

References (28)

1. The importance of dose intensity in chemotherapy of metastatic breast cancer
2. Chemotherapy dose escalation: Case unproven
3. Progress in chemotherapy for metastatic breast cancer
4. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
5. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving a complete remission after intensive doxo
6. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial
7. Conventional-dose chemotherapy compared to high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breat cancer
8. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: Results of the French protocol PEGASE 04
9. Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with blood cell support for metastatic breast cancer: Results of phase I study
10. Repetitive high-dose therapy with peripheral blood progenitor support for metastatic and locally advanced breast cancer
11. Isolex 300i CD34-selected blood cells are capable of supporting multiple cycles of high-dose chemotherapy
12. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
13. A randomized phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen: Preliminary results
14. Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline resistant metastatic breast cancer
15. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
16. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer
17. Peripheral blood CD34-positive cell count reliably predicts autograft yield
18. The ISHAGE guidelines for CD34+ cell determination by flow cytometry
19. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study
20. Comparison of COBE Spectra software version 4.7 and version 6.0 Auto PBSC Program
21. Ifosfamide in combination with paclitaxel or doxorubicin: Regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer
22. 2 of CY
23. Epirubicin and docetaxel is a very effective regimen for peripheral blood progenitor cells mobilization
24. Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells
25. Cyclophosphamide, adriamycin, 5 fluorouracil and G-CSF mobilization achieves high peripheral blood progenitor cell yield which can support multiple cycles of high-dose chemotherapy
26. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
27. Stem cell mobilization in resistant or relapsed lymphoma: Superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide
28. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer